Explore the vast range of titles available.

This phase 3, multiregional, randomized, double-blind, placebo-controlled study assessed the efficacy/safety profile of anacetrapib added to ongoing therapy with statin ± other lipid-modifying therapies in patients with hypercholesterolemia who were not at their low-density lipoprotein (LDL-C) goal (as per the National Cholesterol Education Program Adult Treatment Panel III guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C). Patients on a stable dose of statin ± other lipid-modifying therapies and with LDL-C ≥70 to <115, ≥100 to <145, ≥130, or ≥160 mg/dl for very high, high, moderate, or low CHD risk or at LDL-C goal (per CHD risk category) with HDL-C ≤40 mg/dl were randomized in a ratio of 1:1 to anacetrapib 100 mg (n = 290) or placebo (n = 293) for 24 weeks, followed by a 12-week off-drug phase. The co-primary end points were % change from baseline in LDL-C and HDL-C and the safety profile of anacetrapib. Treatment with anacetrapib reduced LDL-C (BQ) by 37% (95% confidence interval −42.5, −31.0) and increased HDL-C by 118% (95% confidence interval 110.6, 125.7) relative to placebo (p <0.001 for both). Anacetrapib also reduced non-HDL-C, apolipoprotein B, and lipoprotein a and increased apolipoprotein AI versus placebo (p <0.001 for all). There were no clinically meaningful differences between the anacetrapib and placebo groups in the % patients who discontinued drug due to an adverse event or in abnormalities in liver enzymes, creatine kinase, blood pressure, electrolytes, or adjudicated cardiovascular events. Treatment with anacetrapib substantially reduced LDL-C and also increased HDL-C and was well tolerated over 24 weeks in statin-treated patients with hypercholesterolemia or low HDL-C.

Introduction and objective: The placement of short dental implants is used as an alternative treatment modality to bone grafting procedures. The aim of this study was to discuss, through a literature review, the features, indications and biomechanical aspects of short implants, as well as to report the clinical factors that influence on their indication. Literature review and conclusion: It was found that short implants osseointegration can be compromised by risk factors that must be controlled to achieve treatment success. In conclusion, the main indication of short implants is to avoid an invasive surgery at atrophic areas of maxilla and mandible. Furthermore, implant design associated with surface treatment are factors that compensate its short length.

Introduction and objective: The placement of short dental implants is used as an alternative treatment modality to bone grafting procedures. The aim of this study was to discuss, through a literature review, the features, indications and biomechanical aspects of short implants, as well as to report the clinical factors that influence on their indication. Literature review and conclusion: It was found that short implants osseointegration can be compromised by risk factors that must be controlled to achieve treatment success. In conclusion, the main indication of short implants is to avoid an invasive surgery at atrophic areas of maxilla and mandible. Furthermore, implant design associated with surface treatment are factors that compensate its short length.